PPARs: Fatty acid sensors controlling metabolism

Seminars in Cell and Developmental Biology

Volumn 23, Issue 6, 2012, Pages 631-639

  Poulsen, Lars la Cour ^a   Siersbæk, Majken ^a   Mandrup, Susanne ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Fatty acid; Metabolic regulation; Peroxisome proliferator activated receptor; Post translational modifications; Subtype specificity

Indexed keywords

FATTY ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

CELL DIFFERENTIATION; CELL GROWTH; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLIC REGULATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; TISSUE DISTRIBUTION;

EID: 84863111550     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2012.01.003     Document Type: Review

References (127)

1. Aagaard M.M., Siersbaek R., Mandrup S. Molecular basis for gene-specific transactivation by nuclear receptors. Biochim Biophys Acta 2011, 1812:824-835.
2. Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45:120-159.
3. Evans R.M., Barish G.D., Wang Y.X. PPARs and the complex journey to obesity. Nat Med 2004, 10:355-361.
4. Escriva H., Delaunay F., Laudet V. Ligand binding and nuclear receptor evolution. Bioessays 2000, 22:717-727.
5. Chandra V., Huang P., Hamuro Y., Raghuram S., Wang Y., Burris T.P., et al. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. Nature 2008, 456:350-356.
6. Rochel N., Ciesielski F., Godet J., Moman E., Roessle M., Peluso-Iltis C., et al. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat Struct Mol Biol 2011, 18:564-570.
7. Bugge A., Mandrup S. Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation. PPAR Res 2010, 2010.
8. Yu S., Reddy J.K. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta 2007, 1771:936-951.
9. Dyson H.J., Wright P.E. Coupling of folding and binding for unstructured proteins. Curr Opin Struct Biol 2002, 12:54-60.
10. Dunker A.K., Cortese M.S., Romero P., Iakoucheva L.M., Uversky V.N. Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J 2005, 272:5129-5148.
11. Bugge A., Grontved L., Aagaard M.M., Borup R., Mandrup S. The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment. Mol Endocrinol 2009, 23:794-808.
12. Gelman L., Zhou G., Fajas L., Raspe E., Fruchart J.C., Auwerx J. p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem 1999, 274:7681-7688.
13. Grontved L., Madsen M.S., Boergesen M., Roeder R.G., Mandrup S. MED14 tethers mediator to the N-terminal domain of peroxisome proliferator-activated receptor gamma and is required for full transcriptional activity and adipogenesis. Mol Cell Biol 2010, 30:2155-2169.
14. Debril M.B., Gelman L., Fayard E., Annicotte J.S., Rocchi S., Auwerx J. Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit. J Biol Chem 2004, 279:16677-16686.
15. Nielsen R., Grontved L., Stunnenberg H.G., Mandrup S. Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol 2006, 26:5698-5714.
16. Schupp M., Lazar M.A. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem 2010, 285:40409-40415.
17. Xu H.E., Lambert M.H., Montana V.G., Parks D.J., Blanchard S.G., Brown P.J., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999, 3:397-403.
18. Tudor C., Feige J.N., Pingali H., Lohray V.B., Wahli W., Desvergne B., et al. Association with coregulators is the major determinant governing peroxisome proliferator-activated receptor mobility in living cells. J Biol Chem 2007, 282:4417-4426.
19. Molnar F., Matilainen M., Carlberg C. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem 2005, 280:26543-26556.
20. Perissi V., Aggarwal A., Glass C.K., Rose D.W., Rosenfeld M.G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004, 116:511-526.
21. Hartman H.B., Hu X., Tyler K.X., Dalal C.K., Lazar M.A. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002, 277:19754-19761.
22. Kallen C.B., Lazar M.A. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996, 93:5793-5796.
23. Camp H.S., Whitton A.L., Tafuri S.R. PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes. FEBS Lett 1999, 447:186-190.
24. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
25. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10:365-376.
26. LeBrasseur N.K., Kelly M., Tsao T.S., Farmer S.R., Saha A.K., Ruderman N.B., et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006, 291:E175-E181.
27. Tomaru T., Steger D.J., Lefterova M.I., Schupp M., Lazar M.A. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins. J Biol Chem 2009, 284:6116-6125.
28. Schopfer F.J., Cole M.P., Groeger A.L., Chen C.S., Khoo N.K., Woodcock S.R., et al. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem 2010, 285:12321-12333.
29. Gelman L., Feige J.N., Desvergne B. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim Biophys Acta 2007, 1771:1094-1107.
30. Li Y., Lambert M.H., Xu H.E. Activation of nuclear receptors: a perspective from structural genomics. Structure 2003, 11:741-746.
31. Diradourian C., Girard J., Pegorier J.P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005, 87:33-38.
32. Floyd Z.E., Stephens J.M. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem 2002, 277:4062-4068.
33. Hu E., Kim J.B., Sarraf P., Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996, 274:2100-2103.
34. Shao D., Rangwala S.M., Bailey S.T., Krakow S.L., Reginato M.J., Lazar M.A. Interdomain communication regulating ligand binding by PPAR-gamma. Nature 1998, 396:377-380.
35. Juge-Aubry C.E., Hammar E., Siegrist-Kaiser C., Pernin A., Takeshita A., Chin W.W., et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem 1999, 274:10505-10510.
36. Ohshima T., Koga H., Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 2004, 279:29551-29557.
37. Pourcet B., Pineda-Torra I., Derudas B., Staels B., Glineur C. SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. J Biol Chem 2010, 285:5983-5992.
38. Choi J.H., Banks A.S., Estall J.L., Kajimura S., Bostrom P., Laznik D., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466:451-456.
39. Nielsen R., Pedersen T.A., Hagenbeek D., Moulos P., Siersbaek R., Megens E., et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev 2008, 22:2953-2967.
40. Lefterova M.I., Zhang Y., Steger D.J., Schupp M., Schug J., Cristancho A., et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev 2008, 22:2941-2952.
41. IJpenberg A., Jeannin E., Wahli W., Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 1997, 272:20108-20117.
42. Adhikary T., Kaddatz K., Finkernagel F., Schonbauer A., Meissner W., Scharfe M., et al. Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). PLoS One 2011, 6:e16344.
43. Boergesen M., Pedersen T.A., Gross B., van Heeringen S.J., Hagenbeek D., Bindesbøll C., et al. Genome-wide profiling of LXR, RXR and PPARa in mouse liver reveals extensive sharing of binding sites. Molecular and Cellular Biology 2011, 32:852-867.
44. Schmidt S.F., Jorgensen M., Chen Y., Nielsen R., Sandelin A., Mandrup S. Cross species comparison of C/EBPalpha and PPARgamma profiles in mouse and human adipocytes reveals interdependent retention of binding sites. BMC Genomics 2011, 12:152.
45. Lefterova M.I., Steger D.J., Zhuo D., Qatanani M., Mullican S.E., Tuteja G., et al. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. Mol Cell Biol 2010, 30:2078-2089.
46. Siersbaek R., Nielsen R., John S., Sung M.H., Baek S., Loft A., et al. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J 2011, 30:1459-1472.
47. Siersbaek R., Nielsen R., Mandrup S. Transcriptional networks and chromatin remodeling controlling adipogenesis. Trends Endocrinol Metab 2011, 23:56-64.
48. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001, 142:4195-4202.
49. Mueller E., Drori S., Aiyer A., Yie J., Sarraf P., Chen H., et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 2002, 277:41925-41930.
50. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
51. Kannisto K., Chibalin A., Glinghammar B., Zierath J.R., Hamsten A., Ehrenborg E. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise. Int J Mol Med 2006, 17:45-52.
52. Finck B.N., Bernal-Mizrachi C., Han D.H., Coleman T., Sambandam N., LaRiviere L.L., et al. A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes. Cell Metab 2005, 1:133-144.
53. Gan Z., Burkart-Hartman E.M., Han D.H., Finck B., Leone T.C., Smith E.Y., et al. The nuclear receptor PPARbeta/delta programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev 2011, 10.1101/gad.178434.111.
54. Wang Y.X., Zhang C.L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004, 2:e294.
55. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 2003, 100:15924-15929.
56. Gaudel C., Schwartz C., Giordano C., Abumrad N.A., Grimaldi P.A. Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle. Am J Physiol Endocrinol Metab 2008, 295:E297-E304.
57. Kramer D.K., Al-Khalili L., Guigas B., Leng Y., Garcia-Roves P.M., Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 2007, 282:19313-19320.
58. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008, 134:405-415.
59. Peltzer J., Carpentier G., Martelly I., Courty J., Keller A. Transitions towards either slow-oxidative or fast-glycolytic phenotype can be induced in the murine WTt myogenic cell line. J Cell Biochem 2010, 111:82-93.
60. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 2003, 17:2299-2301.
61. Chabowski A., Zendzian-Piotrowska M., Nawrocki A., Gorski J. Not only accumulation, but also saturation status of intramuscular lipids is significantly affected by PPARgamma activation. Acta Physiol (Oxf) 2011, 10.1111/j.1748-1716.2011.02380.x.
62. Norris A.W., Chen L., Fisher S.J., Szanto I., Ristow M., Jozsi A.C., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003, 112:608-618.
63. Hevener A.L., He W., Barak Y., Le J., Bandyopadhyay G., Olson P., et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 2003, 9:1491-1497.
64. Way J.M., Harrington W.W., Brown K.K., Gottschalk W.K., Sundseth S.S., Mansfield T.A., et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001, 142:1269-1277.
65. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004, 10:1245-1250.
66. Gilde A.J., van der Lee K.A., Willemsen P.H., Chinetti G., van der Leij F.R., van der Vusse G.J., et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003, 92:518-524.
67. Montessuit C., Papageorgiou I., Lerch R. Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture. Endocrinology 2008, 149:1064-1074.
68. Burkart E.M., Sambandam N., Han X., Gross R.W., Courtois M., Gierasch C.M., et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 2007, 117:3930-3939.
69. Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.P., et al. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 2005, 16:2395-2402.
70. Minutoli L., Antonuccio P., Polito F., Bitto A., Squadrito F., Irrera N., et al. Peroxisome proliferator activated receptor beta/delta activation prevents extracellular regulated kinase 1/2 phosphorylation and protects the testis from ischemia and reperfusion injury. J Urol 2009, 181:1913-1921.
71. Iwashita A., Muramatsu Y., Yamazaki T., Muramoto M., Kita Y., Yamazaki S., et al. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J Pharmacol Exp Ther 2007, 320:1087-1096.
72. Oka T., Xu J., Molkentin J.D. Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol 2007, 18:117-131.
73. Finck B.N., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121-130.
74. Finck B.N., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 2003, 100:1226-1231.
75. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005, 97:372-379.
76. Son N.H., Park T.S., Yamashita H., Yokoyama M., Huggins L.A., Okajima K., et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007, 117:2791-2801.
77. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312.
78. Schadinger S.E., Bucher N.L., Schreiber B.M., Farmer S.R. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005, 288:E1195-E1205.
79. Mikkelsen T.S., Xu Z., Zhang X., Wang L., Gimble J.M., Lander E.S., et al. Comparative epigenomic analysis of murine and human adipogenesis. Cell 2010, 143:156-169.
80. Ribon V., Johnson J.H., Camp H.S., Saltiel A.R. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 1998, 95:14751-14756.
81. Smith U., Gogg S., Johansson A., Olausson T., Rotter V., Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 2001, 15:215-220.
82. Tzameli I., Fang H., Ollero M., Shi H., Hamm J.K., Kievit P., et al. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem 2004, 279:36093-36102.
83. Walkey C.J., Spiegelman B.M. A functional peroxisome proliferator-activated receptor-gamma ligand-binding domain is not required for adipogenesis. J Biol Chem 2008, 283:24290-24294.
84. Elabd C., Chiellini C., Carmona M., Galitzky J., Cochet O., Petersen R., et al. Human multipotent adipose-derived stem cells differentiate into functional brown adipocytes. Stem Cells 2009, 27:2753-2760.
85. Festuccia W.T., Blanchard P.G., Richard D., Deshaies Y. Basal adrenergic tone is required for maximal stimulation of rat brown adipose tissue UCP1 expression by chronic PPAR-gamma activation. Am J Physiol Regul Integr Comp Physiol 2010, 299:R159-R167.
86. Petrovic N., Walden T.B., Shabalina I.G., Timmons J.A., Cannon B., Nedergaard J. Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J Biol Chem 2010, 285:7153-7164.
87. Matsusue K., Peters J.M., Gonzalez F.J. PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation. FASEB J 2004, 18:1477-1479.
88. Bastie C., Luquet S., Holst D., Jehl-Pietri C., Grimaldi P.A. Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation. J Biol Chem 2000, 275:38768-38773.
89. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 2002, 99:303-308.
90. Peters J.M., Lee S.S., Li W., Ward J.M., Gavrilova O., Everett C., et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000, 20:5119-5128.
91. Roberts L.D., Murray A.J., Menassa D., Ashmore T., Nicholls A.W., Griffin J.L. The contrasting roles of PPARdelta and PPARgamma in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biol 2011, 12:R75.
92. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
93. Barbera M.J., Schluter A., Pedraza N., Iglesias R., Villarroya F., Giralt M. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem 2001, 276:1486-1493.
94. Hondares E., Rosell M., Diaz-Delfin J., Olmos Y., Monsalve M., Iglesias R., et al. PPARalpha induces PGC-1alpha gene expression and contributes to the thermogenic activation of brown fat; involvement of PRDM16. J Biol Chem 2011, 286:43112-43122.
95. Goto T., Lee J.Y., Teraminami A., Kim Y.I., Hirai S., Uemura T., et al. Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. J Lipid Res 2011, 52:873-884.
96. Ribet C., Montastier E., Valle C., Bezaire V., Mazzucotelli A., Mairal A., et al. Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology 2010, 151:123-133.
97. Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999, 103:1489-1498.
98. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999, 96:7473-7478.
99. Sanderson L.M., Boekschoten M.V., Desvergne B., Muller M., Kersten S. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol Genomics 2010, 41:42-52.
100. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5:415-425.
101. Chau M.D., Gao J., Yang Q., Wu Z., Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 2010, 107:12553-12558.
102. Chou C.J., Haluzik M., Gregory C., Dietz K.R., Vinson C., Gavrilova O., et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 2002, 277:24484-24489.
103. Oosterveer M.H., Grefhorst A., van Dijk T.H., Havinga R., Staels B., Kuipers F., et al. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem 2009, 284:34036-34044.
104. Lemberger T., Saladin R., Vazquez M., Assimacopoulos F., Staels B., Desvergne B., et al. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem 1996, 271:1764-1769.
105. Oishi K., Shirai H., Ishida N. CLOCK is involved in the circadian transactivation of peroxisome-proliferator-activated receptor alpha (PPARalpha) in mice. Biochem J 2005, 386:575-581.
106. Gachon F., Leuenberger N., Claudel T., Gos P., Jouffe C., Fleury O.F., et al. Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor alpha (PPARalpha) activity. Proc Natl Acad Sci USA 2011, 108:4794-4799.
107. Patel D.D., Knight B.L., Wiggins D., Humphreys S.M., Gibbons G.F. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. J Lipid Res 2001, 42:328-337.
108. Canaple L., Rambaud J., Dkhissi-Benyahya O., Rayet B., Tan N.S., Michalik L., et al. Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock. Mol Endocrinol 2006, 20:1715-1727.
109. Barroso E., Rodriguez-Calvo R., Serrano-Marco L., Astudillo A.M., Balsinde J., Palomer X., et al. The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation. Endocrinology 2011, 152:1848-1859.
110. Matsusue K., Haluzik M., Lambert G., Yim S.H., Gavrilova O., Ward J.M., et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003, 111:737-747.
111. Moran-Salvador E., Lopez-Parra M., Garcia-Alonso V., Titos E., Martinez-Clemente M., Gonzalez-Periz A., et al. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J 2011, 25:2538-2550.
112. Pettinelli P., Videla L.A. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab 2011, 96:1424-1430.
113. Ravnskjaer K., Frigerio F., Boergesen M., Nielsen T., Maechler P., Mandrup S. PPAR{delta} is a fatty acid sensor, which enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid induced dysfunction. J Lipid Res 2010, 51:1370-1379.
114. Dillon J.S., Yaney G.C., Zhou Y., Voilley N., Bowen S., Chipkin S., et al. Dehydroepiandrosterone sulfate and beta-cell function: enhanced glucose-induced insulin secretion and altered gene expression in rodent pancreatic beta-cells. Diabetes 2000, 49:2012-2020.
115. Rosen E.D., Kulkarni R.N., Sarraf P., Ozcan U., Okada T., Hsu C.H., et al. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 2003, 23:7222-7229.
116. Gupta D., Jetton T.L., Mortensen R.M., Duan S.Z., Peshavaria M., Leahy J.L. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse pdx-1 promoter. J Biol Chem 2008, 283:32462-32470.
117. Laybutt D.R., Sharma A., Sgroi D.C., Gaudet J., Bonner-Weir S., Weir G.C. Genetic regulation of metabolic pathways in beta-cells disrupted by hyperglycemia. J Biol Chem 2002, 277:10912-10921.
118. Zhou Y.T., Shimabukuro M., Wang M.Y., Lee Y., Higa M., Milburn J.L., et al. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci USA 1998, 95:8898-8903.
119. Gupta D., Peshavaria M., Monga N., Jetton T.L., Leahy J.L. Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes. Diabetes 2010, 59:1445-1450.
120. Ravnskjaer K., Boergesen M., Rubi B., Larsen J.K., Nielsen T., Fridriksson J., et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells. Endocrinology 2005, 146:3266-3276.
121. Hellemans K., Kerckhofs K., Hannaert J.C., Martens G., Van V.P., Pipeleers D. Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. FEBS J 2007, 274:6094-6105.
122. Cohen G., Riahi Y., Shamni O., Guichardant M., Chatgilialoglu C., Ferreri C., et al. Role of lipid peroxidation and PPAR-delta in amplifying glucose-stimulated insulin secretion. Diabetes 2011, 60:2830-2842.
123. Sun Y., Zhang L., Gu H.F., Han W., Ren M., Wang F., et al. Peroxisome proliferator-activated receptor-alpha regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate. Endocrinology 2008, 149:662-671.
124. Lalloyer F., Vandewalle B., Percevault F., Torpier G., Kerr-Conte J., Oosterveer M., et al. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 2006, 55:1605-1613.
125. Roduit R., Morin J., Masse F., Segall L., Roche E., Newgard C.B., et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta-cell. J Biol Chem 2000, 275:35799-35806.
126. Boergesen M., Poulsen L.C., Schmidt S.F., Frigerio F., Maechler P., Mandrup S. ChREBP mediates glucose repression of peroxisome proliferator-activated receptor alpha expression in pancreatic beta-cells. J Biol Chem 2011, 286:13214-13225.
127. Ravnskjaer K., Boergesen M., Dalgaard L.T., Mandrup S. Glucose-induced repression of PPARalpha gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation. J Mol Endocrinol 2006, 36:289-299.